Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16403251 | 0.90 | CHRNA7 (0.81) | CHRNA7MAPK1CYP2D6MAPT | |
| SCHEMBL7167824 | 0.89 | AR (0.59) | CHRNA7ARMAPT | |
| SCHEMBL3027578 | 0.84 | CHRNA7 (0.77) | CHRNA7MAPK1CYP2D6 | |
| SCHEMBL5922342 | 0.84 | CHRNA7 (0.72) | CHRNA7MAPK1MAPT | |
| SCHEMBL2888752 | 0.84 | CHRNA7 (0.72) | CHRNA7MAPK1MAPT | |
| SCHEMBL19808409 | 0.84 | CHRNA7 (0.74) | CHRNA7MAPK1CYP2D6MAPT | |
| SCHEMBL3015623 | 0.83 | CHRNA7 (1.00) | CHRNA7CYP2D6 | |
| SCHEMBL3020486 | 0.82 | CHRNA7 (0.98) | CHRNA7CYP2D6 | |
| SCHEMBL3035477 | 0.81 | CHRNA7 (0.78) | CHRNA7MAPK1CYP2D6 | |
| SCHEMBL7192981 | 0.79 | LMNA (0.62) | CHRNA7ARMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885MAPK1 4366/4885CYP2D6 253/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | CHRNA7 4801/4885MAPK1 4366/4885CYP2D6 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.